Background Tumour heterogeneity significantly impacts biomarker reliability in non-small cell lung cancer (NSCLC), such as lactate dehydrogenase A (LDHA) and Talin-1, thus complicating the validation of their diagnostic utility. This evidence concerns the gene LDHA and neoplasm.